Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delayed versus standard Prograf with induction therapy followed by conversion to Advagraf in DCD kidney transplant recipients
ChiCTR1800016648Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Sep 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in end-stage kidney disease (ESKD) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Incidence of delayed graft function within 1 week post transplantation. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
tacrolimus
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR1800016648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016648.